Bullous Pemphigoid Burden of Disease and Diagnosis
Bottom left-hand image reprinted from Dermatologic Clinics, Vol 29/No. 3, Schmidt E, et al, Clinical features and practical diagnosis of bullous pemphigoid, pp427-438, Copyright 2011, with permission Elsevier. Far bottom-right image reprinted from DermNet New Zealand. Original image located at: https://dermnetnz.org/topics/bullous-pemphigoid-images. Far top-right image reprinted with permission from Science Photo Library. Original image located at: https://www.sciencephoto.com/media/1227663/view
Left image reprinted from DermNet New Zealand. Original image located at: https://dermnetnz.org/topics/bullous-pemphigoid-images
*May persist for several weeks or months before the formation of bullae, or it may remain non-bullous indefinitely in atypical variants.
BP, bullous pemphigoid; QoL, quality of life.
1. Schmidt E, Zillikens D. Lancet. 2013;381:320-332.
2. Zeidler C, et al. Front Immunol. 2019;10:1303.
3. Di Zenzo G, et al. Clin Dermatol. 2012;30:3-16.
4. Kridin K, Ludwig RJ. Front Med (Lausanne). 2018;5:220.
5. Tamzazian S, Simpson CL. JAAD Case Rep. 2020;6(11):1173-1178.
6. PCDS. Accessed September 13, 2024. https://www.pcds.org.uk/clinical-guidance/bullous-pemphigoid1
7. Science Photo Library. Accessed September 13, 2024. https://www.sciencephoto.com/media/1227663/view 8. Schmidt E, et al. Dermatol Clin. 2011;29:427 438.
9. DermNet New Zealand. Accessed September 13, 2024. https://dermnetnz.org/topics/bullous-pemphigoid-images
10. Schmidt E, Groves R. Immunobullous diseases. In: Griffith C, Barker J, Bleiker T, Hussain W, Simpson RS (Eds). Rook’s Textbook of Dermatology. Chichester. Wiley-Blackwell; 2024:50.1 50.61.
11. Borradori L, et al. J Eur Acad Dermatol Venereol. 2022;36(10):1689-1704.
12. van Beek N, etal. Expert Rev Clin Immunol. 2016;12:267-277.
13. Witte M, et al. Front Med. 2018;5:296.
14. James W, Elston D, Treat J, et al. Andrews’ Diseases of the Skin: Clinical Dermatology. 13th ed, 2019; Elsevier.
15. Hammers CM, Stanley JR. Annu Rev Pathol. 2016;11:175-197.
16. Pratasava V, et al. Medicina (Kaunas). 2021; 4;57(10).
17. Miyamoto D, et al. An Bras Dermatol. 2019;94(2):133-146.
18. Lu L, et al. J Cosmet Dermatol. 2022;21(10):4818-4835.
19. Persson MSM, et al. Br J Dermatol. 2021;184(1):68-77.
20. Kouris A, et al. An Bras Dermatol. 2016;91(5):601-603.
21. deGrazia TM, et al. J Invest Dermatol. 2019;139:b14.
22. Kluger N, et al. Clin Cosmet Invest Dermatol. 2020;13:73-76.
23. Han A, Zeichner JA. J Clin Aesthet Dermatol. 2009;2(5):19-28.
24. Penha MA, et al. An Bras Dermatol. 2015;90(2):190- 194.
25. Venning VA, et al. Br J Dermatol. 2012;167(6):1200-14.
26. Le ST, et al. JAMA Dermatol. 2024;160(1):107-109.
27. Langan SM, et al. J Invest Derm. 2011;131:631-636.
28. Huttelmaier J, et al. Front Immunol. 2023;14:1196999.
29. Kibsgaard L, et al. Acta Derm Venereol. 2015;95:307-311.
30. Lee J, et al. Front Immunol. 2019;10.
Patient morbidity and mortality in BP
Many factors, including older age and multimorbidity, are associated with mortality in bullous pemphigoid. Read this article to find out more
What is Bullous Pemphigoid
The heterogeneous presentation of bullous pemphigoid may shed light on why patients are underdiagnosed. Read the article to learn more
Treatments and challenges for bullous pemphigoid
Systemic corticosteroids and other immunosuppressants are the current mainstay of therapy but carry risks for patients with bullous pemphigoid. Read this article to find out more